This is Tom Lamb's Typepad Profile.
Join Typepad and start following Tom Lamb's activity
Join Now!
Already a member? Sign In
Tom Lamb
Wilmington, NC, USA
Tom Lamb is a lawyer who represents patients and their family in drug injury lawsuits.
Interests: law, news, information, drugs, legal, medical, fda, pharmaceutical, medications, side-effects, drug-injury, drug-safety, regulatory
Recent Activity
Despite recent published studies and articles, the FDA has yet to confirm whether SGLT-2 inhibitor diabetes drugs lead to an increased risk of strokes. Continue reading
Posted yesterday at Drug Safety Developments
The FDA Briefing Materials For A June 2017 Advisory Committee Meeting On Victoza Include A Discussion Of This Safety Issue (Posted by Tom Lamb at On June 20, 2017 there will be an FDA Advisory Committee meeting to discuss Novo Nordisk's supplemental New Drug Application (sNDA) for approval of Victoza® (liraglutide) injection to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and high cardiovascular risk, given as an adjunct to standard treatment of cardiovascular risk factors. In more detail, this FDA Advisory Committee will discuss the results of the so-called LEADER trial: “Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results - A long-term, multi-center, international, randomized double-blind, placebo-controlled trial to determine liraglutide effects on cardiovascular events.” In advance of this meeting we reviewed the FDA Briefing Document for this Endocrinologic and Metabolic Drugs Advisory Committee Meeting (EMDAC), which includes a section titled "ONCOLOGY CONSULT: PANCREATIC CANCER". Before we get into that material, here are some previous articles which provide background information: Pancreatic Cancer As A Side Effect Of Diabetes Drugs Bydureon, Byetta, Januvia, And Victoza Byetta / Januvia / Victoza: Update... Continue reading
Posted 3 days ago at Drug Injury Watch
Debra: To start, I am sorry to hear about the unfortunate loss of your husband. As regards your question, I am not aware of any such lawsuits -- but that is not to say there aren't any. I wish you the best in all aspects going forward. Tom Lamb
1 reply
If the drug you are inquiring about is metformin, then "No" I do not know any lawyers handling these cases. Tom Lamb
1 reply
A recent study revealed that type 2 diabetes drug Invokana has significant cardiovascular benefits, but double the risk of lower-limb amputations. Continue reading
Posted Jun 13, 2017 at Drug Safety Developments
AbbVie, the manufacturer of bipolar drug Depakote, was recently forced to pay $15 million to a child born with spina bifida due to Depakote exposure. Continue reading
Posted Jun 12, 2017 at Drug Safety Developments
Study Compared Newly Initiated Use Of SGLT2 Inhibitor To New Initiation Of Another Class Of Diabetes Drugs To Assess The DKA Side Effect (Posted by Tom Lamb at All of these newer diabetes medicines are part of the Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors class of drugs: Invokana (canagliflozin) Invokamet (canagliflozin and metformin) Invokamet XR (canagliflozin and metformin extended-release) Farxiga (dapagliflozin) Xigduo XR (dapagliflozin and metformin extended-release) Qtern (dapagliflozin and saxagliptin) Jardiance (empagliflozin) Glyxambi (empagliflozin and linagliptin) Synjardy (empagliflozin and metformin hydrochloride) Synjardy XR (empagliflozin and metformin hydrochloride) The SGLT2 inhibitor class of diabetes drugs is approved by the FDA for treatment of type 2 diabetes (T2D). A "To the Editor" letter in the June 8, 2017 edition of The New England Journal of Medicine (NEJM), titled "Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor", is likely causing some concerns among doctors and patients about the safety of Jardiance, Invokana, Farxiga, and the other SGLT2 inhibitors. From the start of that letter we get some introductory information about this drug-safety concern raised for these newer diabetes drugs: Inhibitors of sodium–glucose cotransporter 2 (SGLT2) decrease plasma glucose by blocking the reabsorption of glucose at the proximal tubule. Case reports have... Continue reading
Posted Jun 8, 2017 at Drug Injury Watch
The FDA recently warned that IBS drug Viberzi can cause serious pancreatitis in patients without a gallbladder, resulting in hospitalizations or death. Continue reading
Posted Jun 6, 2017 at Drug Safety Developments
Health Canada calls for warnings on the connection between diabetes drugs and severe joint pain based on existing medical literature and the FDA's warnings. Continue reading
Posted Jun 2, 2017 at Drug Safety Developments
Drug Regulatory Agency Has Requested Additional Safety Information From Some Manufacturers Of Direct-Acting Antivirals (DAAs) (Posted by Tom Lamb at The May 2017 edition of Health Product InfoWatch included this report, "Summary Safety Review - Direct-Acting Antivirals - Assessing the Potential Risk of Liver Cancer Recurrence", which was issued on April 27, 2017 by Health Canada. From the Key Messages part of this drug safety report concerning Sovaldi, Harvoni, and other Direct-Acting Antivirals (DAAs), we get these three main points: Direct-acting antivirals (DAAs) are prescription drugs authorized for sale in Canada to treat chronic hepatitis C virus (HCV) infection in adult patients, which is a serious condition that can result in decreased liver function, serious scarring of the liver (cirrhosis) or liver cancer. Health Canada reviewed the potential risk of liver cancer coming back (recurrence) with the use of DAAs, following the publication of a study suggesting this potential risk. Health Canada’s review concluded that there was not enough information to establish a link between DAAs and liver cancer recurrence. Health Canada has requested additional safety information from some manufacturers of DAAs. In more detail, from the Safety Review Findings part of same report we get this additional information:... Continue reading
Posted Jun 1, 2017 at Drug Injury Watch
Contrary to prior studies conducted on the subject, a new study suggests that there is no link between erectile dysfunction drugs and melanoma skin cancer. Continue reading
Posted May 30, 2017 at Drug Safety Developments
Ocrevus - Progressive Multifocal Leukoencephalopathy (PML) Reported As Possible Side Effect In Germany, Says Drug Maker Roche (Posted by Tom Lamb at In March 2017 the FDA approved Ocrevus (ocrelizumab injection) for the treatment of adult patients with relapsing or primary progressive forms of multiple sclerosis (MS). According to this May 22, 2017 article, "Top 8 New Drugs to Watch for 2021", Ocrevus is projected to be a so-called "blockbuster drug" within the next several years: The 2017 “Drugs to Watch” report from Clarivate Analytics Cortellis Competitive Intelligence, predicts that Ocrevus (ocrelizumab, from Genentech and Roche), will be a top seller in coming years. “Twice yearly injection reduces the rate of relapse of the disease by 46% more than that of the former standard of care, Rebif,” wrote Alexandra Kibble, senior editor for Clarivate, in a blog post. As a result, Ocrevus will produce a projected $3.33 billion in sales in 2021. In addition, Ocrevus is the first drug to prove effective in primary progressive MS, an aggressive form. “The drug also delays disease progression and reduces the number of new brain lesions,” Kibble wrote However, this May 24, 2017 Reuters news report, "Deadly brain infection in German MS... Continue reading
Posted May 25, 2017 at Drug Injury Watch
Current U.S. Version Of Full Prescribing Information Document For Aranesp Mentions Skin Rash Among Other Serious Allergic Reactions (Posted by Tom Lamb at Aranesp (darbepoetin alfa) products for subcutaneous and intravenous use are approved by the FDA for two indications: (1) anemia due to chronic kidney disease; and, (2) anemia due to chemotherapy in patients with cancer. From the Warnings and Precautions section of the current Full Prescribing Information document for ARANESP® (darbepoetin alfa) injection (accessed 5/18/17): 5.7 Serious Allergic Reactions Serious allergic reactions, including anaphylactic reactions, angioedema, bronchospasm, skin rash, and urticaria may occur with Aranesp. Immediately and permanently discontinue Aranesp and administer appropriate therapy if a serious allergic or anaphylactic reaction occurs. [emphasis added] However, it seems that Health Canada wants a more clear or stronger warning about skin-related adverse reactions associated with Aranesp use. On May 5. 2017 the Canadian drug regulatory agency issued this Dear Healthcare Professional Letter: "ARANESP - Risk of Severe Skin Reactions: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis". From this recent Health Canada Aranesp alert we get this updated drug safety information: In some patients, ARANESP has been associated with severe skin reactions, including life-threatening reactions called Stevens-Johnson syndrome (SJS) and toxic... Continue reading
Posted May 18, 2017 at Drug Injury Watch
After conducting several studies on the effects of diabetes drugs like Invokana / Invokamet, researchers found that the risk of amputations has doubled. Continue reading
Posted May 17, 2017 at Drug Safety Developments
With the emergence of the theory that bacterial contamination of breast implants is to blame for rare cancer, questions of accountability also arise. Continue reading
Posted May 15, 2017 at Drug Safety Developments
This Consolidated Litigation Involves Farxiga And Xigduo XR; Side Effects Include Diabetic Ketoacidosis And Kidney Damage (Posted by Tom Lamb at By means of this post, we are updating our March 8, 2017 article, "Pending Motion Requests Multidistrict Litigation (MDL) For Farxiga And Xigduo XR Lawsuits Filed In Federal Court". On April 6, 2017 the United States Judicial Panel On Multidistrict Litigation (JPML) issued this document, "IN RE: FARXIGA (DAPAGLIFLOZIN) PRODUCTS LIABILITY LITIGATION TRANSFER ORDER -- MDL No. 2776", from which we get the following information: The eighteen actions involve allegations that ingestion of the drug Farxiga may cause a variety of injuries, including diabetic ketoacidosis and kidney damage, and that defendants Bristol-Myers Squibb Co., AstraZeneca Pharmaceuticals LP, AstraZeneca LP, AstraZeneca PLC, and AstraZeneca AB (collectively, Bristol-Myers/AstraZeneca), which developed, manufactured, and marketed the drugs, failed to adequately test the drugs and warn of their risks. Farxiga and its sister drug Xigduo XR belong to a class of diabetes drugs known as Sodium Glucose Cotransporter 2 (SGLT2) inhibitors. Other SLGT2 inhibitors include Invokana (canagliflozin) and Jardiance (empagliflozin).... On the basis of the papers filed and the hearing session held, we find that these actions involve common questions of fact, and... Continue reading
Posted May 12, 2017 at Drug Injury Watch
FDA-Funded Study About The Use Of Polyethylene Glycol In The Pediatric Population Currently Underway At Children's Hospital Of Philadelphia (Posted by Tom Lamb at MiraLAX is a popular over-the-counter laxative medicine from Bayer Healthcare LLC. Its active ingredient is Polyethylene Glycol 3350. MiraLAX was initially approved by the FDA as a prescription drug on February 18, 1999. From the DIRECTIONS section of the MiraLAX® Drug Facts part of the packaging (viewed 5/4/17) we get the following relevant information: Do not take more than directed unless advised by your doctor. ... Adults and children 17 years of age and older: fill to top of white section in cap which is marked to indicate the correct dose (17 g) stir and dissolve in any 4 to 8 ounces of beverage (cold, hot or room temperature), then drink use once a day use no more than 7 days Children 16 years of age or under: ask a doctor. Despite the fact that MiraLAX is not intended for use by young children, pediatricians and other doctors have been prescribing or recommending MiraLAX use in that patient population for many years, apparently. Generally, this use of MiraLAX by children pursuant to their doctor's guidance... Continue reading
Posted May 4, 2017 at Drug Injury Watch
Kristen: To start, I am saddened to hear about the recent loss of your father. I am continuing to monitor this Harvoni - liver cancer situation. Here is a more recent (April 2017) article I wrote about it: Harvoni / Sovaldi: Spring 2017 Update On Issue Of Liver Cancer Recurrence After Using Direct-Acting Antiviral "Hep-C" Drugs At the present time we are not handling Harvoni liver cancer drug injury cases -- rather, only liver failure, acute liver injury, severe liver damage, and reactivation of hepatitis B cases. However, this may change if the medical evidence continues to show there may be an association, or "link", between Harvoni (as well as other direct-acting antivirals hepatitis C drugs) and liver cancer. Tom Lamb
1 reply
Thank you for leaving this Comment. My law firm cannot help you with this matter, as we are not handling metformin drug injury cases. I suggest you contact another law firm at this time. I wish you the best in all aspects going forward. Tom Lamb
1 reply
Thank you for leaving this Comment. My law firm cannot help you with this matter, as we are not handling Effient drug injury cases. I suggest you contact another law firm at this time. I wish you the best in all aspects going forward. Tom Lamb
1 reply
Thank you for leaving this Comment. My law firm cannot help you with this matter, as we are not handling metformin drug injury cases. I suggest you contact another law firm at this time. I wish you the best in all aspects going forward. Tom Lamb
1 reply
More Medical Studies Reach Different Conclusions About Whether New Hepatitis C Virus Medications Might Cause The Return Of Liver Cancer (Posted by Tom Lamb at We continue to hear reports of patients who used Harvoni or Sovaldi for to cure their hepatitis C only to afterwards have the return of their earlier liver cancer, which had been in remission before their "Hep-C" was treated by one of these so-called "direct-acting antiviral" (DAA) drugs. As background, we first wrote about this still-emerging drug safety issue about a year ago, in April 2016, when we posted this article, "European Drug Regulators Consider Whether Harvoni, Sovaldi, And Other New "Hep-C" Drugs May Cause Liver Cancer Return, Hepatitis B Reactivation". More recently, in January 2017, we posted this article, "Is Liver Cancer Associated With Harvoni, Sovaldi, And Other Direct-Acting Antiviral Medications For Hepatitis C?" Earlier today we found an April 25, 2017 news report, "The Link Between Direct-Acting Antiviral Therapy for Hepatitis C Virus and Liver Cancer Risk Continues To Be Debated", which was published on the PracticeUpdate website (free registration required). This recent report draws upon eight new medical studies which were presented at the International Liver Congress 2017, from April 19... Continue reading
Posted Apr 27, 2017 at Drug Injury Watch
I am saddened to hear about the loss of your father. Please understand, however, that because I am not a physician but only an attorney I am not in a position to give any medical opinion as regards your father's situation. I wish you and your family the best in all aspects going forward. Tom Lamb
1 reply
Several theories on how a rare cancer develops from breast implants have arisen. Though rare, this disease severely affects the women diagnosed with it. Continue reading
Posted Apr 20, 2017 at Drug Safety Developments
Focus On Medical Journal Articles About The Diagnosis And Treatment Of This Breast Implants Lymphoma Cancer Published In 2015 (Posted by Tom Lamb at In January 2011 the U.S. Food and Drug Administration (FDA) first announced a possible association between breast implants and anaplastic large cell lymphoma (ALCL), which was likened to systemic ALCL and treated accordingly. See "Anaplastic Large Cell Lymphoma (ALCL) In Women with Breast Implants: Preliminary FDA Findings and Analyses". Over the next couple of years there were some, but not many, medical journal articles reporting on findings about breast implant-associated ALCL (BIA-ALCL) having to do with diagnosis and treatment of this rare form of lymphoma. For example, from the September 2013 edition of Current Hematologic Malignancy Reports, there was this article, "Breast implant-associated anaplastic large cell lymphoma: a systematic review of the literature and mini-meta analysis": Breast implant-associated ALCL (BIA-ALCL) is a rare, but likely under-reported entity, which most commonly presents with an effusion developing between the breast implant and the host fibrous capsule that surrounds it. It has been described in association with breast implants used for post-cancer reconstructive surgery and when implanted for purely cosmetic reasons. Two different presentations are seen; presentation with... Continue reading
Posted Apr 20, 2017 at Drug Injury Watch